Zyomyx to Develop Biochips Using Dyax s Phage Display Technology

Mar 27, 2001

NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.

The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

WHO Panel Announced

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

Research Reproducibility Scores

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

Tests for All Diagnosed

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

This Week in Science

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Main menu